We imagine. We create. We innovate.
Imcomet was founded on the belief that progress in dermatology is often held back not by biology, but by the difficulty of accessing it in clinical trials. We work alongside dermatologists, clinical researchers, and pharmaceutical teams to make the study of local skin biology more patient friendly and clinically feasible.
Founder and CEO of Imcomet with over 18 years of experience in skin biology, pharmaceutical development, and clinical operations. Varsha holds a PhD in Skin Biology from Leiden University and leads the company’s strategy, partnerships, and scientific direction, focused on improving access to local skin biology in clinical research.
Director of Quality at Imcomet, responsible for the company’s quality and regulatory strategy. Erik brings over 20 years of experience across medical devices, in vitro diagnostics, and the pharmaceutical industry, with a strong track record in ISO 13485, MDR, and FDA-aligned quality systems. His focus is on building pragmatic, compliant foundations that support clinical studies and commercial readiness.
Business Development Director at Imcomet, supporting partnering, licensing, and collaboration with pharmaceutical companies, academic research institutes, and contract research organizations. Martin brings over 20 years of experience in business development across the pharmaceutical and life sciences sectors. He holds a PhD in Bio-Organic Chemistry from Delft University of Technology.
Associate Scientist at Imcomet, supporting experimental validation, technology optimization, and device prototyping. Kyriaki has a background in protein biotechnology and translational research, with hands-on experience in cell culture, molecular biology, biomaterials, and microfluidics. Her work focuses on translating laboratory research into robust, reproducible technology for biomarker-based dermatology research.
